

4.0.03 DOC Cmte minutes

Rheumatoid Arthritis Committee meeting

Date: 14/09/2016

Location: Wolfson & Exhibition Area, Academy of Medical Sciences, 41
Portland Place, London W1B 1QH

Minutes: Final



| Committee members present: | |
|-----------------------------------|---------------------------|
| Stephen Ward (Chair) | (Present for notes 1 – 5) |
| Vicky Chamberlain | (Present for notes 1 – 5) |
| Jennie Jones | (Present for notes 1 – 5) |
| Bruce Kirkham | (Present for notes 1 – 5) |
| Frank McKenna | (Present for notes 1 – 5) |
| Benjamin Parker | (Present for notes 1 – 5) |
| Heidi Siddle | (Present for notes 1 – 5) |
| Louise Warburton | (Present for notes 1 – 5) |

| In attendance: | | |
|-----------------------|---|---------------------------|
| Joanna Ashe | Senior Information Specialist, NGC | (Present for notes 1 – 5) |
| Serena Carville | Guideline Lead/Associate Director, NGC | (Present for notes 1 – 5) |
| Lefteris Floros | Health Economist, NGC | (Present for notes 1 – 5) |
| Martin Harker | Senior Health Economist, NGC | (Present for notes 1 – 5) |
| Ben Pordes | Project Manager, NGC | (Present for notes 1 – 5) |
| Jacqui Real | Senior Research Fellow, NGC | (Present for notes 1 – 5) |
| Emma Chambers | Public Involvement Advisor, NICE | (Present for notes 1 – 3) |
| Caroline Keir | Guidelines Commissioning Manager, NICE | (Present for notes 1 – 5) |

| Observers: |
|-------------------|
| None |

4.0.03 DOC Cmte minutes

| | |
|-------------------|----------------------|
| Apologies: | |
| Alex Allen | Research Fellow, NGC |
| Ailsa Bosworth | Committee member |
| Anupama Nandagudi | Committee member |

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the first meeting on Rheumatoid Arthritis. The Committee members and attendees introduced themselves.

No members of the public asked to observe the meeting.

The Chair informed the Committee that apologies had been received. These are noted above.

2. Declarations of interest

The Chair asked everyone to verbally declare any interests.

| Name | Job title, organisation | Declarations of Interest, date declared | Type of interest | Decision taken |
|-------------------|--|---|-----------------------------------|-------------------------|
| Vicky Chamberlain | Rheumatology Nurse Specialist, Trafford Hospital Central Manchester NHS Foundation Trust | Past Trustee and Board member arthritis and Musculoskeletal alliance – resigned July 2016 | Personal, non-financial, specific | Declare and participate |
| Vicky Chamberlain | Rheumatology Nurse Specialist, Trafford Hospital Central Manchester NHS Foundation Trust | Nurse Advisor for the National Rheumatoid Arthritis Alliance | Personal, non-financial, specific | Declare and participate |
| Jennie Jones | Lay member | Trustee for NRAS. NRAS receives educational grants from industry (AbbVie, Eli Lilly, Medac, Merck, Pfizer, Roche, | Non-personal, financial, non- | Declare and participate |

4.0.03 DOC Cmte minutes

| | | | | |
|---------------|--|---|--|--|
| | | Sandoz and UCB). | specific | |
| Jennie Jones | Lay member | Held 40 GlaxoSmithKline shares worth approximately £580 as part of my SIPP. These have been sold. | Personal, financial, specific | Declare and participate |
| Bruce Kirkham | Consultant Rheumatologist, Guy's & St Thomas' NHS Foundation Trust | Advisory boards attended: 1. Novartis: secukinumab anti-IL-17 therapy in psoriatic arthritis - European meeting July 2016 2. Lilly: Scientific advisor for anti-IL-17 therapy in psoriatic arthritis, ixekizumab - Global Scientific Advisory Board June 2016 3. Lilly: Baricitinib as potential therapy in RA - Global Advisory Board July 2016 4. Sandoz: Biosimilar development in RA - UK advisory board February 2016 | 1-4: Personal, financial, non-specific | 1-4: Declare and participate |
| Bruce Kirkham | Consultant Rheumatologist, Guy's & St Thomas' NHS Foundation Trust | Speaker Bureaus for: 1. Novartis (psoriatic arthritis) - Last meeting July 2016 2. Janssen (psoriatic arthritis) - Last meeting will be September 2016 3. Bristol Myer Squibb - Last meeting September 2015 | 1-3: Personal, financial, non-specific | 1-3: Declare and participate |
| Bruce Kirkham | Consultant Rheumatologist, Guy's & St Thomas' NHS Foundation Trust | Clinical trial work (all contracts are with Guy's & St Thomas' Hospital BK is a PI or CI): 1. Lilly RA studies in long-term extension. UK chief Investigator since baricitinib Phase III studies began in 2013, all now in long-term extension Phase, PI at my site for 3 studies, which finish in 2 years 2. Novartis (secukinumab in psoriatic arthritis) UK Chief Investigator for one secukinumab study in PsA and one in AS, PI at my site for 3 secukinumab studies in psoriatic arthritis, beginning in 2012, planned finish in 2 years. | 1. Non-personal, financial, non-specific 2. Non-personal, financial, non-specific | 1. Declare and participate 2. Declare and participate |

4.0.03 DOC Cmte minutes

| | | | | |
|---------------|---|--|--|------------------------------|
| Bruce Kirkham | Consultant Rheumatologist, Guy's & St Thomas' NHS Foundation Trust | Partnership Research Support for Investigator initiated studies (IIS). All these contracts are with Guy's & St Thomas' Hospital, BK is PI or CI. IIS arrangements are that the data is owned by the investigator and published in peer reviews publications: 1. AbbVie - Our RA Centre database was initially set up in 2006 with Charitable funds. This large database of routine practice needs funds to support analysis. This project finishes in November 2016. 2. Roche (RA Centre database analysis support) - As above, analysis of RA Centre database, this project finishes in October 2016. 3. Novartis, basic science in psoriatic arthritis. Study exploring IL-17 biology in psoriatic arthritis in partnership with my university King's College London colleagues, no therapies included, project finishes in May 2017. | 1-3: Non-personal, financial, non-specific | 1-3: Declare and participate |
| Frank McKenna | Consultant Rheumatologist, Trafford General Hospital, Central Manchester Foundation Trust | Current investigator for etanercept biosimilar (Sandoz) and attendance at one advisory board related to the compound. | Non-personal, financial, non-specific | Declare and participate |
| Frank McKenna | Consultant Rheumatologist, Trafford General Hospital, Central Manchester Foundation Trust | Honorarium for attendance at a Sanofi advisory board in January 2016 on biosimilar etanercept in development. | Personal, financial, non-specific | Declare and participate |
| Frank McKenna | Consultant Rheumatologist, Trafford | Gave a lecture at a satellite meeting at a EULAR 2016 conference sponsored by | Personal, financial, non- | Declare and participate |

4.0.03 DOC Cmte minutes

| | | | | |
|------------|---|---|--|--|
| a | General Hospital, Central Manchester Foundation Trust | Janssen in June. An honorarium was received. | specific | te |
| Ben Parker | Consultant Rheumatologist, Kellgren Centre for Rheumatology, Manchester Royal Infirmary | Genzyme funding to University of Manchester for study of neurocognitive function in systemic lupus erythematosus (2013-16; co-applicant) expires March 2017. | Personal, financial, non-specific | Declare and participate |
| Ben Parker | Consultant Rheumatologist, Kellgren Centre for Rheumatology, Manchester Royal Infirmary | Honoraria for advisory boards: 1. UCB Pharma - one-off event April 2016 2. AbbVie - open ended - no further events planned | 1. Personal, financial, non-specific 2. Personal, financial, non-specific | 1. Declare and participate 2. Declare and participate |
| Ben Parker | Consultant Rheumatologist, Kellgren Centre for Rheumatology, Manchester Royal Infirmary | Speaker honoraria from: 1. AbbVie - intermittent, no further events planned 2. Pfizer - intermittent, event scheduled for November 2016 3. BMS - intermittent, no further events planned | 1-3: Personal, financial, non-specific | 1-3: Declare and participate |
| Ben Parker | Consultant Rheumatologist, Kellgren Centre for Rheumatology, Manchester Royal Infirmary | Travel funded by AbbVie (American College Rheumatology, Washington DC, November 2016) single event. | Travel expenses only | None |
| Ben Parker | Consultant Rheumatologist, Kellgren Centre for Rheumatology, Manchester Royal Infirmary | Sub-investigator - A randomised open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for response-resistance to rituximab vs tocilizumab in RA (R4-RA). Sponsored by Queen Mary University. | Non-personal, financial, non-specific | Declare and participate |
| Ben Parker | Consultant Rheumatologist, Kellgren | Sub-investigator - Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept. | Non-personal, financial, | Declare and participa |

4.0.03 DOC Cmte minutes

| | | | | |
|--------------|---|---|---------------------------------------|-------------------------|
| | Centre for Rheumatology, Manchester Royal Infirmary | Sponsored by BMS. | non-specific | te |
| Ben Parker | Consultant Rheumatologist, Kellgren Centre for Rheumatology, Manchester Royal Infirmary | Sub-investigator - A study to Investigate the role of Interleukin Seventeen (IL-17) and Th17 pathway activation in RA patients with inadequate response to anti-TNF-alpha therapies – “THERAPIST” (Th17 Responses Evaluated in RA Patients on Inhibitors of TNF α). Sponsored by Queen Mary University. | Non-personal, financial, non-specific | Declare and participate |
| Ben Parker | Consultant Rheumatologist, Kellgren Centre for Rheumatology, Manchester Royal Infirmary | Sub-investigator - A non-interventional study to assess the effectiveness of certolizumab pegol in patients with axial spondyloarthritis in daily practice. Sponsored by UCB BIOPHARMA. | Non-personal, financial, non-specific | Declare and participate |
| Ben Parker | Consultant Rheumatologist, Kellgren Centre for Rheumatology, Manchester Royal Infirmary | Sub-investigator - An open label randomised multicentre controlled trial of rituximab and MMF without oral steroids for the treatment of lupus nephritis. Sponsored by Imperial College London. | Non-personal, financial, non-specific | Declare and participate |
| Heidi Siddle | Principal Podiatrist, Leeds Teaching Hospitals NHS Trust | NIHR funded Clinical Lectureship - Tight control of inflammatory foot and ankle disease in patients with rheumatoid arthritis: March 2015 – February 2019 | Personal, financial, non-specific | Declare and participate |
| Heidi Siddle | Principal Podiatrist, Leeds Teaching Hospitals NHS Trust | Funds received from EULAR to develop recommendations for non-medical health professional using musculoskeletal ultrasound: July 2015 – present | Personal, financial, non-specific | Declare and participate |
| Heidi Siddle | Principal Podiatrist, Leeds Teaching Hospitals NHS Trust | Co-editor for a book “The foot and ankle in rheumatology” due for publication 2017 by Oxford University Press. | Personal, financial, non-specific | Declare and participate |
| Louise | GP with | Has written a chapter in a book | Personal, | Declare |

4.0.03 DOC Cmte minutes

| | | | | |
|------------------|---|--|---------------------------------------|-------------------------|
| Warburton | special interest in Musculoskeletal Medicine, Telford Musculoskeletal Service | on osteoporosis, due to be published | non-financial, non-specific | and participate |
| Louise Warburton | GP with special interest in Musculoskeletal Medicine, Telford Musculoskeletal Service | Trustee of the Arthritis and Musculoskeletal Alliance (ARMA), which receives funding from industry. | Non-personal, financial, non-specific | Declare and participate |
| Louise Warburton | GP with special interest in Musculoskeletal Medicine, Telford Musculoskeletal Service | Attending BRITSpA 2016 Meeting (incorporating the New Perspectives in Research and Management in AS) in September. | Travel and accommodation only | None |

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Presentations

The Chair introduced Caroline Keir, Guidelines Commissioning Manager, NICE who gave a presentation on NICE and the guideline development process.

The Chair introduced Emma Chambers, Public Involvement Advisor, NICE who gave a presentation on public involvement in the guideline development process.

The Chair introduced Serena Carville, Associate Director, NGC who gave a presentation on the working practices of the National Guideline Centre and the NICE policy for declaring and dealing with conflicts of interest.

The Chair introduced Joanna Ashe, Senior Information Specialist, NGC who gave a presentation on the role of the Information Specialist.

The Chair introduced Jacqui Real, Senior Research Fellow, NGC who gave a presentation on the role of the Research Fellows.

The Chair introduced Lefteris Floros, Health Economist, NGC, who gave a

4.0.03 DOC Cmte minutes

presentation on the role of the Health Economists.

The Chair gave a presentation on the Guideline Scope.

Jacqui Real gave a presentation on the process of developing a review protocol.

4. Discussion

The Committee discussed the draft protocol for the question: *In adults with rheumatoid arthritis, what is the clinical and cost effectiveness of analgesics, including NSAIDs, paracetamol and opiates?* and were given the opportunity to ask questions and make changes. The Committee agreed the protocol.

The Committee discussed the draft protocol for the question: *In adults with rheumatoid arthritis, what is the clinical and cost effectiveness of corticosteroids?* and were given the opportunity to ask questions and make changes.

5. Any other business

Ben Pordes explained that the SharePoint site will be live for Guideline Committee meeting 2.

Ben Pordes informed the Committee of the short courses offered by the NGC.

Date of next meeting: 07/11/2016

Location of next meeting: Boardroom, National Guideline Centre, 5th Floor, 180 Great Portland St, London W1W 5QZ